Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE-XT)
Conditions
Diseases of the Musculoskeletal System
Phase III
Volunteers
Health Professionals
What is the purpose of this trial?
Brief Summary:
To evaluate the safety and tolerability of FG-3019 in subjects with IPF, and the efficacy of FG-3019 in slowing the loss of forced vital capacity (FVC) and the progression of IPF in these subjects.
- Ages40 years - 80 years
- GenderBoth
- Trial withRa Pharmaceuticals, Inc.
- Start Date07/01/2020
- End Date12/31/2020
For more information about this study, contact:
Danielle Carlson
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigator
- Last Updated07/15/2021
- Study HIC#2000026786